Abstract View: 73

Research Article

Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice

Amir Daei Farshchi Adli ORCID logo, Rana Jahanban-Esfahlan, Khaled Seidi, Davoud Farajzadeh, Nosratollah Zarghami* ORCID logo


Tumor vascular targeting (TVT) appeared as an appealing approach to fight cancer, though, the results from the clinical trials and drugs in the market were proved otherwise. The promise of anti-angiogenic therapy as the leading TVT strategy was negatively affected by the discovery that tumor vascularization can occur non-angiogenic mechanisms such as co-option. An additional strategy is the induction of tumor vascular infarction and ischemia. Such that we used truncated coagulase (tCoa) coupled with tumor endothelial targeting moieties to produce tCoa-NGR fusion proteins. We showed that tCoa-NGR can bypass coagulation cascade to induce selective vascular thrombosis and infarction of mild and highly proliferative solid tumors in mice. Moreover, combination therapy can be used to improve the potential of cancer vascular targeting modalities. Herein, we report a combination of tCoa-NGR with the vascular disrupting agent, Vadimezan. Our results show that the synergistic work of these two agents can significantly suppress the growth of B16-F10 melanoma tumors in C57/BL6 mice. For the first time, we used the simultaneous benefits of two strategies for inducing thrombosis and the destruction of tumor vasculature as spatial co-operation. The tCoa-NGR induces thrombosis which reduces blood flow in the peripheral tumor region. And combined with the action of Vadimezan, which targets inner tumor mass, growth and proliferation of melanoma tumors can be significantly suppressed.
Keywords: DMXAA, tumor vascular infarction, B16-F10 melanoma cells, cancer therapy
First Name
Last Name
Email Address
Security code

Abstract View: 73

Your browser does not support the canvas element.

PDF Download: 0

Your browser does not support the canvas element.

Submitted: 25 Jan 2020
Revision: 01 Mar 2020
Accepted: 15 Apr 2020
ePublished: 15 Apr 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)